Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $256.2 million.

  • Ligand Pharmaceuticals' Cash & Current Investments rose 202.55% to $664.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 48.21%. This contributed to the annual value of $256.2 million for FY2024, which is 50.41% up from last year.
  • Ligand Pharmaceuticals' Cash & Current Investments amounted to $256.2 million in FY2024, which was up 50.41% from $170.3 million recorded in FY2023.
  • Ligand Pharmaceuticals' 5-year Cash & Current Investments high stood at $411.2 million for FY2020, and its period low was $170.3 million during FY2023.
  • In the last 3 years, Ligand Pharmaceuticals' Cash & Current Investments had a median value of $211.9 million in 2022 and averaged $212.8 million.
  • In the last 5 years, Ligand Pharmaceuticals' Cash & Current Investments crashed by 61.57% in 2020 and then soared by 50.41% in 2024.
  • Ligand Pharmaceuticals' Cash & Current Investments (Yearly) stood at $411.2 million in 2020, then dropped by 17.04% to $341.1 million in 2021, then tumbled by 37.89% to $211.9 million in 2022, then fell by 19.62% to $170.3 million in 2023, then soared by 50.41% to $256.2 million in 2024.